Albireo Pharma (NASDAQ:ALBO) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.44) by $0.09, Morningstar.com reports. The firm had revenue of $1.25 million for the quarter, compared to analyst estimates of $1.11 million. Albireo Pharma had a negative return on equity of 47.03% and a negative net margin of 2,900.81%.
Shares of ALBO stock traded down $1.89 during trading on Friday, reaching $22.86. 60,801 shares of the company’s stock were exchanged, compared to its average volume of 46,349. The stock has a market capitalization of $275.23 million, a PE ratio of -5.80 and a beta of 1.52. Albireo Pharma has a twelve month low of $19.10 and a twelve month high of $38.69. The business has a fifty day moving average price of $28.98.
Several research analysts have weighed in on the company. William Blair reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Monday, July 15th. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, April 17th. HC Wainwright reaffirmed a “buy” rating and set a $62.00 price target on shares of Albireo Pharma in a research report on Wednesday, July 10th. BidaskClub lowered Albireo Pharma from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, ValuEngine raised Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $60.33.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Read More: How to Trade Using Analysts Ratings
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.